Back to Ovarian Cancer
NCT02873962
NCT02873962
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with ovarian cancer, fallopian tube cancer, or peritoneal cancer, confirmed by a tissue or cell sample — any cancer type or grade is accepted
- You have already received a first round of platinum-based chemotherapy (a common type of cancer treatment)
- Your cancer has come back after standard treatment
- Your cancer came back between 2 months and 12 months after your last platinum-based chemotherapy (the exact time window may depend on which group within the trial you are being considered for — confirm with trial site)
- You have received no more than 3 chemotherapy treatments in total (there is no limit on prior hormone therapies)
- Your cancer can be measured on scans using standard measurement guidelines
- You have previously received the drug bevacizumab, as long as you did not have serious harmful reactions to it
- You have NOT previously received certain immunotherapy drugs that target the immune system's "checkpoint" pathways (such as anti-PD-1, anti-PD-L1, anti-CTLA-4 treatments)
- Any hormone therapy you were taking has been stopped at least 1 week before starting this trial (hormone replacement therapy for menopause symptoms may be continued)
- You are 18 years old or older
- Your doctor estimates you have a life expectancy of more than 6 months
- You are generally well enough to care for yourself and carry out light activity (confirm with trial site what this means for you)
- Your recent blood test results meet certain minimum levels for blood cells, kidney function, liver function, and blood clotting — taken within 14 days before joining (confirm specific values with trial site)
- You have had a previous skin cancer (certain types), early-stage breast or cervical abnormality, or certain early-stage cancers that were fully treated, with no signs of return for at least 3 years
- You have a tumor that can be biopsied and are willing to have a biopsy before treatment, or you have a stored tumor sample taken within the last 20 months
- If you are a woman who could become pregnant, you must agree to use effective contraception for 6 months after the last dose of treatment
- If you are a woman who could become pregnant, you must have a negative pregnancy test within 24 hours before starting treatment
- You are not currently breastfeeding
- You are able to understand and sign a consent form agreeing to take part
- For certain groups (Cohorts 2 and 3): You have been tested for a gene change called BRCA and do not carry a harmful BRCA mutation (confirm with trial site)
Who may not be able to join:
- Your cancer came back less than 2 months after your last platinum-based chemotherapy (called "platinum-refractory" disease)
- Your cancer came back more than 12 months after your last platinum-based chemotherapy
- You have had chemotherapy or radiotherapy within the last 3 weeks, or you are still experiencing side effects from a recent treatment
- You are currently taking part in another clinical trial or have done so within the past 4 weeks
- You are using natural herbal products or folk remedies, or are unwilling to stop using them during the trial
- You have had a serious allergic reaction to bevacizumab or to drugs similar to nivolumab or bevacizumab
- You currently have active cancer that has spread to the brain or the lining around the brain, unless it was treated at least 6 months ago with no signs of return
- You have certain heart conditions, including a heart attack in the last 6 months, unstable chest pain, severe heart failure, significant heart valve problems, or abnormal heart rhythms requiring a pacemaker (confirm full list with trial site)
- You have had a hypertensive crisis (a sudden dangerous rise in blood pressure) at any time
- Your blood pressure is not well controlled (above 140/90 mmHg)
- You have significant blood vessel disease, including a history of stroke, mini-stroke, or brain bleed
- Your heart's electrical activity shows certain abnormalities on a heart tracing (ECG) test
- You have significant protein or blood in your urine
- You have had a bowel blockage, a hole in your bowel, or an abscess in your abdomen within the last 6 months, or currently have any signs of bowel problems
- You
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Active, Not Recruiting
Phase
Phase 2
Sponsor
Dana-Farber Cancer Institute
Registry
clinicaltrials_gov
Start date
10 November 2016
Est. completion
1 February 2025
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Cohort 1: Objective Response Rate; Cohort 2: Objective Response Rate; Cohort 3: Tolerability
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.